Multiple Myeloma · line 3 · Ciltacabtagene autoleucel (cilta-cel) BCMA CAR-T for R/R multiple myeloma after ≥3 prior lines — single infusion after Flu/Cy lymphodepletion (CARTITUDE-1)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	3
Track	aggressive
Linked regimen	`REG-CILTACEL-MM-3L`

ID	`IND-MM-RR-3L-CILTACEL`
Type	Indication
Status	reviewed 2026-04-29 \| pending_clinical_signoff
Diseases	`DIS-MM`
Sources	`SRC-CARTITUDE-1-BERDEJA-2021` `SRC-ESMO-MM-2023` `SRC-NCCN-MM-2025`

Notes

STUB — requires two clinical co-lead signoffs before publication (CHARTER §6.1). Sibling to existing IND-MM-4L-CILTACEL-CART (4L framing); this entity uses RR-3L framing per Tier-2 manifest (tier2-ind-mm-2026-05-01-021). CARTITUDE-1 source available; NCCN-MM-2025 + ESMO-MM-2023 supplementary citations satisfy Q4 ≥2-source axis.

Used By

Indication

IND-MM-RR-2L-CILTACEL - IND-MM-RR-2L-CILTACEL
IND-MM-RR-3L-IDECEL - IND-MM-RR-3L-IDECEL